Regeneron Pharmaceuticals, Inc. (REGN) Given Outperform Rating at Raymond James Financial, Inc.
Raymond James Financial, Inc. reaffirmed their outperform rating on shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) in a research note issued to investors on Wednesday. The firm currently has a $566.00 target price on the biopharmaceutical company’s stock.
A number of other brokerages also recently weighed in on REGN. Leerink Swann reiterated a positive rating and set a $552.00 price target (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. Sanford C. Bernstein reiterated an outperform rating on shares of Regeneron Pharmaceuticals in a report on Thursday, May 25th. Piper Jaffray Companies reiterated an overweight rating and set a $557.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st. Evercore ISI started coverage on Regeneron Pharmaceuticals in a report on Wednesday, August 16th. They set an outperform rating and a $605.00 price target on the stock. Finally, Barclays PLC reiterated an equal weight rating and set a $450.00 price target (up previously from $400.00) on shares of Regeneron Pharmaceuticals in a report on Saturday, July 22nd. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the stock. Regeneron Pharmaceuticals currently has an average rating of Hold and a consensus price target of $496.35.
Regeneron Pharmaceuticals (REGN) traded down 5.48% during trading on Wednesday, reaching $472.82. The company had a trading volume of 632,254 shares. The stock has a 50 day moving average price of $485.86 and a 200 day moving average price of $442.34. Regeneron Pharmaceuticals has a 12 month low of $325.35 and a 12 month high of $543.55. The firm has a market capitalization of $50.13 billion, a price-to-earnings ratio of 47.43 and a beta of 1.65.
Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its earnings results on Thursday, August 3rd. The biopharmaceutical company reported $4.17 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.67 by $1.50. The business had revenue of $1.47 billion for the quarter, compared to analysts’ expectations of $1.36 billion. Regeneron Pharmaceuticals had a return on equity of 25.58% and a net margin of 22.05%. The company’s quarterly revenue was up 21.2% on a year-over-year basis. During the same period in the previous year, the firm posted $2.82 EPS. On average, equities research analysts predict that Regeneron Pharmaceuticals will post $14.90 earnings per share for the current year.
ILLEGAL ACTIVITY NOTICE: This report was first posted by TheOlympiaReport and is the property of of TheOlympiaReport. If you are reading this report on another domain, it was stolen and republished in violation of international copyright law. The original version of this report can be read at https://theolympiareport.com/2017/09/07/regeneron-pharmaceuticals-inc-regn-given-outperform-rating-at-raymond-james-financial-inc.html.
In related news, CFO Robert E. Landry sold 189 shares of the business’s stock in a transaction dated Tuesday, September 5th. The stock was sold at an average price of $501.06, for a total transaction of $94,700.34. Following the completion of the transaction, the chief financial officer now owns 10,099 shares of the company’s stock, valued at approximately $5,060,204.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Michael S. Aberman sold 2,269 shares of the business’s stock in a transaction dated Thursday, June 22nd. The stock was sold at an average price of $532.42, for a total value of $1,208,060.98. Following the transaction, the senior vice president now directly owns 9,193 shares of the company’s stock, valued at approximately $4,894,537.06. The disclosure for this sale can be found here. Insiders have sold a total of 130,257 shares of company stock valued at $62,227,944 in the last three months. 10.40% of the stock is owned by insiders.
Institutional investors and hedge funds have recently modified their holdings of the stock. Dupont Capital Management Corp bought a new position in Regeneron Pharmaceuticals during the second quarter valued at about $220,000. National Pension Service increased its stake in Regeneron Pharmaceuticals by 10.8% during the second quarter. National Pension Service now owns 66,518 shares of the biopharmaceutical company’s stock valued at $33,920,000 after acquiring an additional 6,481 shares during the period. Blair William & Co. IL increased its stake in Regeneron Pharmaceuticals by 4.8% during the second quarter. Blair William & Co. IL now owns 1,713 shares of the biopharmaceutical company’s stock valued at $841,000 after acquiring an additional 79 shares during the period. Princeton Capital Management Inc. increased its stake in Regeneron Pharmaceuticals by 6.7% during the first quarter. Princeton Capital Management Inc. now owns 2,496 shares of the biopharmaceutical company’s stock valued at $967,000 after acquiring an additional 157 shares during the period. Finally, Principal Financial Group Inc. increased its stake in Regeneron Pharmaceuticals by 2.4% during the second quarter. Principal Financial Group Inc. now owns 115,201 shares of the biopharmaceutical company’s stock valued at $56,580,000 after acquiring an additional 2,646 shares during the period. Hedge funds and other institutional investors own 67.96% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Receive News & Ratings for Regeneron Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.